RYTM241220C65000
- 1.44
- -0.03-2.04%
Rhythm Pharmaceuticals Newsroom
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $69
Stifel Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $78
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $65
Rhythm Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $58 to $80
TD Cowen Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals' Advancements in Setmelanotide Trials Signal Strong Buy Rating
Buy Rating Justified for Rhythm Pharmaceuticals Due to Promising Data and Strategic Study Expansion
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $69
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $59 to $80
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $64 to $72
Rhythm Pharmaceuticals Is Maintained at Buy by Needham
Rhythm Pharmaceuticals Analyst Ratings
Rhythm Pharmaceuticals: Strong Financial Performance and Pipeline Progress Justify Buy Rating
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $55
Stifel Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $64
Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $53
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $55
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $77
Rhythm Pharmaceuticals Analyst Ratings